Opportunity Information: Apply for RFA CA 14 003
Apply for RFA CA 14 003
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 20, 2013 and posted on Dec 20, 2013.
- Applicants must submit their applications by Sep 18, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- The number of recipients for this funding is limited to 22 candidate(s).
- Eligible applicants include: County governments Special district governments Small businesses Public housing authorities/Indian housing authorities City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public and State controlled institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) opportunity (Funding Opportunity Number RFA-CA-14-003) is a National Institutes of Health (NIH) grant program aimed at supporting exploratory, early stage projects that create or significantly advance highly innovative technologies for molecular or cellular analysis in cancer. The central focus is on technology inception and development rather than mature tools that are already broadly validated. The program is designed to help investigators take bold, technically novel ideas and push them to the point where feasibility for a cancer-relevant application can be demonstrated.
A key feature of this announcement is its interest in both brand-new concepts and "emerging technologies" with strong transformative potential. In this context, an emerging technology means a platform or method that has moved beyond an initial prototype stage but has not yet been evaluated for the specific cancer-related use proposed in the application. Because of that gap, it must require substantial modification or adaptation to work in the intended cancer setting. In other words, the FOA is not just looking for routine application of existing tools to cancer; it is looking for meaningful technical innovation where the work is necessary to make the technology viable for cancer molecular or cellular characterization.
The emphasis is on molecular analysis technologies that could significantly change how researchers study the molecular and cellular bases of cancer. Projects are expected to aim for step-change improvements in what can be measured, how accurately it can be measured, at what scale, and at what cost, speed, or usability. While the technology may ultimately be broadly applicable across biomedical research, it must be grounded in analyzing cancer through molecular and/or cellular characterization, rather than, for example, purely anatomical imaging or non-molecular approaches.
If successful, the technologies developed under this FOA are expected to accelerate or enhance many areas of cancer research and public health impact. The announcement explicitly highlights potential downstream value in cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and efforts related to cancer health disparities. The underlying idea is that better tools for molecular and cellular analysis can unlock new biological insights, enable earlier or more precise detection, improve classification of disease, and support more tailored or effective interventions, including in populations where cancer outcomes differ due to access, biology, or social determinants of health.
From an administrative standpoint, this is a discretionary grant opportunity using the NIH R21 mechanism, which typically supports exploratory and developmental research. The opportunity was posted on December 20, 2013, with an original and current closing date of September 18, 2014, and an archive date of October 19, 2014. NIH anticipated making about 22 awards, with an estimated total program funding level of $5,000,000. The listed award ceiling is $200,000, and there is no cost sharing or matching requirement.
Eligibility is broad and includes many organization types across the public, private, and nonprofit sectors. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (including those with and without 501(c)(3) status, other than institutions of higher education); for-profit organizations (including small businesses and other for-profits); public housing authorities and Indian housing authorities; and Native American tribal governments and tribal organizations (including federally recognized and other than federally recognized entities). The eligibility list also explicitly includes a range of mission-focused institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations).
The opportunity is associated with CFDA program areas tied to cancer research across the continuum: 93.393 (Cancer Cause and Prevention Research), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research). Overall, the FOA is best understood as a targeted push to seed high-risk, high-reward technology development that can reshape how cancer is interrogated at the molecular and cellular level, with the longer-term goal of enabling faster progress in research and improved outcomes in prevention, detection, diagnosis, and treatment.
Frequently Asked Questions (FAQs)
What is the funding opportunity called?
The opportunity is titled Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-CA-14-003.
Which agency runs this program?
This is a National Institutes of Health (NIH) grant program.
What is the main goal of this grant?
The main goal is to support exploratory, early stage projects that create or significantly advance highly innovative technologies for molecular or cellular analysis in cancer research. The focus is on technology inception and development, not on mature tools that are already broadly validated.
What type of projects is this FOA trying to fund?
The FOA is designed for bold, technically novel ideas that can be pushed far enough to demonstrate feasibility for a cancer-relevant application.
Does the program support both brand-new and emerging technologies?
Yes. The announcement is interested in brand-new concepts and also emerging technologies that have strong transformative potential.
What does "emerging technology" mean in this FOA?
In this FOA, an emerging technology is a platform or method that has moved beyond an initial prototype stage, but has not yet been evaluated for the specific cancer-related use proposed in the application. Because of that, it must require substantial modification or adaptation to work in the intended cancer setting.
Is routine application of existing tools to cancer a fit for this opportunity?
No. The FOA is not looking for routine application of existing tools to cancer. It is looking for meaningful technical innovation where the proposed work is necessary to make the technology viable for cancer molecular or cellular characterization.
What research focus area must the technology address?
The technology must be grounded in analyzing cancer through molecular and/or cellular characterization.
What kinds of improvements are projects expected to target?
Projects are expected to aim for step-change improvements in what can be measured, how accurately it can be measured, and at what scale, as well as potential gains in cost, speed, or usability.
Does the technology need to be broadly applicable outside cancer research?
It can ultimately be broadly applicable across biomedical research, but it must be grounded in cancer-relevant molecular and/or cellular analysis as described in the FOA.
What downstream impacts does the FOA highlight if technologies are successful?
The FOA highlights potential downstream value across cancer research and public health impact areas, including cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and efforts related to cancer health disparities.
What grant mechanism is used?
This is a discretionary grant opportunity using the NIH R21 mechanism, which typically supports exploratory and developmental research.
When was the opportunity posted?
The opportunity was posted on December 20, 2013.
What are the closing dates listed for this FOA?
The original and current closing date is September 18, 2014.
When is (or was) the archive date?
The archive date is October 19, 2014.
How many awards did NIH anticipate making?
NIH anticipated making about 22 awards.
What is the estimated total program funding level?
The estimated total program funding level is $5,000,000.
What is the listed award ceiling?
The listed award ceiling is $200,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes many organization types across the public, private, and nonprofit sectors, including government entities, higher education institutions, nonprofits, and for-profit organizations.
Are state and local governments eligible applicants?
Yes. Eligible applicants include state, county, city or township, and special district governments.
Are schools and universities eligible?
Yes. The eligibility list includes independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. Eligible applicants include nonprofit organizations with 501(c)(3) status and without 501(c)(3) status (other than institutions of higher education).
Are for-profit organizations eligible?
Yes. For-profit organizations, including small businesses and other for-profits, are eligible.
Are public housing authorities eligible?
Yes. The eligibility list includes public housing authorities and Indian housing authorities.
Are Tribal governments and Tribal organizations eligible?
Yes. Eligible applicants include Native American tribal governments and tribal organizations, including federally recognized and other than federally recognized entities.
Are specific mission-focused institutions explicitly included?
Yes. The eligibility list explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. The eligibility list explicitly includes faith-based or community-based organizations.
Are federal agencies eligible to apply?
Yes. The eligibility list includes eligible federal agencies.
Are U.S. territories or possessions eligible?
Yes. The eligibility list includes U.S. territories or possessions.
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility list includes non-U.S. entities (foreign organizations).
Which CFDA program areas are associated with this FOA?
The FOA is associated with CFDA program areas 93.393 (Cancer Cause and Prevention Research), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research).
How should this FOA be understood at a high level?
It is a targeted push to seed high-risk, high-reward technology development that can reshape how cancer is interrogated at the molecular and cellular level, with longer-term goals tied to progress in prevention, detection, diagnosis, and treatment.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Early Stage Development of Innovative Technologies for Biospecimen Science (R21)
Previous opportunity: Cyberlearning and Future Learning Technologies
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 14 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 14 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 14 005 Funding Number: RFA CA 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 14 006 Funding Number: RFA CA 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 14 004 Funding Number: RFA CA 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Using Social Media to Understand and Address Substance Use and Addiction (R01) Apply for RFA CA 14 008 Funding Number: RFA CA 14 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Using Social Media to Understand and Address Substance Use and Addiction (R21) Apply for RFA CA 14 009 Funding Number: RFA CA 14 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PA 14 061 Funding Number: PA 14 061 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PA 14 062 Funding Number: PA 14 062 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PA 14 063 Funding Number: PA 14 063 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (U01) Apply for PAR 14 067 Funding Number: PAR 14 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Centers of Excellence in Self Management Building Research Teams for the Future (P20) Apply for RFA NR 14 001 Funding Number: RFA NR 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Centers of Excellence in Self Management Research (P30) Apply for RFA NR 14 002 Funding Number: RFA NR 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $480,000 |
| Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44) Apply for RFA DA 15 001 Funding Number: RFA DA 15 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42) Apply for RFA DA 15 002 Funding Number: RFA DA 15 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development Centers of Excellence Cooperative Program (U54) Apply for RFA DA 15 003 Funding Number: RFA DA 15 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroimmune Signaling in Substance Use Disorders (R01) Apply for PA 14 084 Funding Number: PA 14 084 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroimmune Signaling and Function in Substance Use Disorders (R21) Apply for PA 14 083 Funding Number: PA 14 083 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01) Apply for PAR 14 085 Funding Number: PAR 14 085 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01) Apply for PAR 14 086 Funding Number: PAR 14 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 14 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.